Procore signs multi-year strategic collaboration agreement with AWS
EXTON, Pa. -On Thursday, West Pharmaceutical (TADAWUL:2070) Services, Inc. (NYSE:WST) reported first-quarter earnings that surpassed analyst expectations.
The company’s shares were up 3.13% in premarket trading following the release.
The pharmaceutical packaging company posted adjusted earnings per share of $1.45, beating the consensus estimate of $1.23. Revenue came in at $698 million, topping expectations of $684.94 million and representing a 0.4% increase YoY.
"I am pleased to report we delivered a solid first quarter as both revenues and adjusted-diluted EPS exceeded our first quarter guidance," said Eric M. Green, President, CEO and Chair of the Board.
West Pharmaceutical raised its full-year 2025 guidance, now expecting revenue between $2.945 billion and $2.975 billion, up from its previous forecast of $2.875 billion to $2.905 billion. The company also increased its adjusted EPS outlook to $6.15-$6.35, compared to the prior range of $6.00-$6.20.
However, the new guidance still falls short of analyst projections for 2025 revenue of $3.093 billion and EPS of $7.02.
The company’s Proprietary Products segment saw net sales grow 0.6% to $563.0 million, with organic growth of 2.4%. High-value products represented over 73% of segment sales, driven by demand for self-injection devices.
West Pharmaceutical’s Board of Directors approved a third-quarter 2025 dividend of $0.21 per share, payable on August 6, 2025.
The company repurchased 550,281 shares for $133.5 million during the quarter at an average price of $242.63 per share.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.